The FDA on March 30, 2020 approved IMFINZI® in combination with Etoposide and either Carboplatin or Cisplatin as first-line treatment of patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC). IMFINZI® is a product of AstraZeneca.
Other Pages – Bottom Ad
Advertisement
Subscribe
